Copyright
©The Author(s) 2023.
World J Virol. Jan 25, 2023; 12(1): 30-43
Published online Jan 25, 2023. doi: 10.5501/wjv.v12.i1.30
Published online Jan 25, 2023. doi: 10.5501/wjv.v12.i1.30
Table 4 Studies showing outcomes and predictors of severity in hepatitis B virus-infected patients with coronavirus disease 2019
Ref. | Study | Patients | Results | Predictors |
Yang et al[38] | Single centre retrospective study | Patients with HBV infection out of 2899 COVID patients. Resolved hepatitis B (n = 503); HBeAg (-) CHB/infection (n = 44); HBeAg (+) CHB/infection (n = 55); HBV reactivation (n = 6) | HBeAg (+) CHB/infection and HBV reactivation were associated with more abnormal liver function, severe disease, longer ICU stay, and death | Increased ICU admission (HR: 1.86) and mortality (HR: 3.19) in HBeAg (+) CHB/infection |
Choe et al[40] | Nationwide population-based cohort study | 676 chronic HBV infection cases (19160 COVID-19 cases) | Mortality in HBV infected vs non-infected patients with COVID-19: 8.2% vs 13.5% | No difference in mortality, ICU admission, or organ failure |
Wang et al[8] | Multicentre retrospective cohort study | 109 CHB and 327 non-CHB patients with COVID-19 | CHB vs non-CHB patients: Severe disease (27.5% vs 12.84%) and more dyspnoea (55.05% vs 43.12%) and mechanical ventilation requirement (22.49% vs 7.95%) in CHB | Increased mortality in CHB patients (OR: 3.748). Predictors of mortality: AST; ALT; ALP; Bilirubin; LDH; Elevated D-dimer. Protective effect: ALB (HR: 0.13); ALB/GLO (HR: 0.123) |
Yip et al[44] | Retrospective cohort study | Current (353) and past HBV infection (359) out of total 5639 COVID cases | Mortality in current HBV vs past HBV vs non-HBV infection: 2.3% vs 5.8% vs 2.2% | Acute liver injury associated with mortality (aHR: 2.45), more than current (aHR: 1.29) or past (aHR: 0.90) HBV infection |
Kang et al[42] | Nationwide cohort study | 7723 COVID-19 cases and 46231 controls | Lower SARS-CoV-2 positivity rate in CHB, after adjusting for comorbidities (aOR: 0.65) | Reduced SARS-CoV-2 positivity (aOR: 0.49) on antivirals |
Liu et al[39] | Retrospective cohort study | 347 COVID-19 patients (21 vs 326 with or without chronic HBV infection) | Severe COVID-19 in 30% vs 31.4% in the HBV vs non-HBV group | Similar SARS-CoV-2 clearance and severe COVID-19 |
- Citation: Walia D, Saraya A, Gunjan D. COVID-19 in patients with pre-existing chronic liver disease – predictors of outcomes. World J Virol 2023; 12(1): 30-43
- URL: https://www.wjgnet.com/2220-3249/full/v12/i1/30.htm
- DOI: https://dx.doi.org/10.5501/wjv.v12.i1.30